news
Desidustat prevents development of ARDS in Phase II COVID-19 trial
In a Phase IIb trial, hospitalised COVID-19 patients treated with desidustat did not develop acute respiratory distress syndrome (ARDS).
List view / Grid view
Therapeutics
Filter the results
news
EC approves RINVOQ (upadacitinib) to treat active psoriatic arthritis
AbbVie's RINVOQ (upadacitinib) has been approved in the EU to treat adult patients with active psoriatic arthritis (PsA).
![Vial labelled heparin. [Credit: SamaraHeisz5 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Heparin-300x278.jpg)
![Vial labelled heparin. [Credit: SamaraHeisz5 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Heparin-scaled.jpg)
news
Increased heparin dose reduces need for life support in hospitalised COVID-19 patients
Interim data from 1,000 hospitalised patients with moderate COVID-19 symptoms shows that full doses of heparin can improve patient outcomes and could reduce ICU burden.
news
XPro1595 significantly improves neurodegeneration in AD trial
Treatment with XPro1595 for three months caused significant changes in neurodegeneration, synaptic function and neuroinflammation.
news
NICE recommends new CAR T-cell therapy to treat mantle cell lymphoma
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
news
Voclosporin approved by FDA to treat lupus nephritis
The FDA has approved Aurinia Pharmaceuticals' LupkynisTM(voclosporin) for the treatment of lupus nephritis, alongside standard-of-care.
news
FDA approves first extended-release injectable, complete regimen for HIV
The approval of Cabenuva (cabotegravir and rilpivirine, injectable formulation) means HIV infected adults could receive once-monthly injections to manage their condition.
news
Phase II trial to establish whether alisporivir can prevent COVID-19 progression
The trial will primarily assess whether alisporivir (Debio 025) can significantly reduce COVID-19 viral load in hospitalised COVID-19 patients with moderate symptoms.
article
The pandemic and the pharmaceutical world
Pharmacist Ezeokafor Ifeoma Charity explores to what extent COVID-19 has prompted the growth of the pharmaceutical industry.
news
Blood test can identify COVID-19 patients at high risk of life-threatening complications
The rapid blood test could be used to identify hospitalised COVID-19 patients who may benefit from investigational treatments and early interventions.
video
HIV treatments: an interview with Dr Jaime Oliver Vigueras
EPR's Victoria Rees interviews Dr Jaime Oliver Vigueras from Janssen to discuss rilpivirine, Janssen's long acting monthly injectable HIV treatment.
news
New system could deliver schizophrenia medicine directly to brain
A team has created a nasal spray as a drug delivery system to get schizophrenia medication directly to the brain.
news
Trial to evaluate inhaled COVID-19 therapy finishes enrolment
The pilot study will determine whether an inhaled formulation of ensifentrine can expedite the recovery of patients hospitalised with COVID-19.
news
US could purchase over 1.5 million doses of Regeneron’s COVID-19 antibody cocktail
The additional doses of casirivimab and imdevimab, two monoclonal antibodies, will be used in non-hospitalised COVID-19 patients.
news
Baricitinib and remdesivir reduce time to recovery in COVID-19 patients
A clinical trial in hospitalised COVID-19 patients has demonstrated that baricitinib and remdesivir reduce time to recovery.